RxDoctor Payments Data

Misty Lewis, APRN

Psychiatric/Mental Health · Augusta, GANPI 1831760255

Payments from drug & device makers

$2,538in general payments, 2019–2025

Across 66 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$688
  • AbbVie$357
  • Vanda Pharmaceuticals Inc.$280
  • Johnson & Johnson$179
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$144
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • plus $754 from 14 others

What the payments were for

  • Travel & lodging$68827%
  • Food & beverage$1,85173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,538 in reported general payments places this provider in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$28,196
Medicare patients
38
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl32$61,172
Abilify MaintenaAripiprazole14$42,224
CaplytaLumateperone Tosylate13$21,008
Aripiprazole53$8,050
Venlafaxine Hcl ErVenlafaxine Hcl73$4,250
Bupropion XlBupropion Hcl78$2,338
Oxcarbazepine11$1,950
Quetiapine Fumarate56$1,469
Trazodone Hcl49$1,461
Hydroxyzine Hcl34$1,115
Lamotrigine46$901
Bupropion Hcl SrBupropion Hcl23$862
Gabapentin48$798
Duloxetine Hcl21$727
Ondansetron OdtOndansetron11$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$357$61,17232 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$107$42,22414 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$82$21,00813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →